Angelo Ruggiero

List of Publications by Citations

Source: https://exaly.com/author-pdf/4625836/angelo-ruggiero-publications-by-citations.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16 415 54 11 h-index g-index citations papers 2.6 69 4.81 947 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
54	Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 328-329	2.8	35
53	Teledermatology for acne during COVID-19: high patientsSsatisfaction in spite of the emergency. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e662-e663	4.6	26
52	Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: Preliminary data of a real-life 16-week retrospective study. <i>Dermatologic Therapy</i> , 2020 , 33, e14144	2.2	25
51	Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e249	4.6	21
50	Telemedicine and support groups could be used to improve adherence to treatment and health-related quality of life in patients affected by inflammatory skin conditions during the COVID-19 pandemic. <i>Clinical and Experimental Dermatology</i> , 2020 , 45, 749	1.8	21
49	Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. <i>Dermatologic Therapy</i> , 2021 , 34, e14673	2.2	18
48	Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. <i>Journal of Dermatological Treatment</i> , 2020 , 1-5	2.8	17
47	Safety of dupilumab in atopic patients during COVID-19 outbreak. <i>Journal of Dermatological Treatment</i> , 2020 , 1-2	2.8	12
46	Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa. <i>Dermatologic Therapy</i> , 2020 , 33, e13756	2.2	12
45	Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 1028-1030	4.5	12
44	Teledermatology and chronic skin diseases: Real life experience in a Southern Italian Dermatologic Centre. <i>Dermatologic Therapy</i> , 2020 , 33, e13839	2.2	11
43	Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. <i>Clinical and Experimental Dermatology</i> , 2021 ,	1.8	11
42	A case of erythrodermic psoriasis successfully treated with guselkumab. <i>Dermatologic Therapy</i> , 2020 , 33, e13238	2.2	11
41	Reply to "Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre" by Sotiriou E etlal. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 ,	4.6	11
40	Community Knowledge About the Use, Reuse, Disinfection and Disposal of Masks and Filtering Facepiece Respirators: Results of a Study Conducted in a Dermatology Clinic at the University of Naples in Italy. <i>Journal of Community Health</i> , 2021 , 46, 786-793	4	10
39	May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions?. <i>Medical Hypotheses</i> , 2020 , 143, 109853	3.8	10
38	Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1485-1492	4.6	10

(2021-2021)

37	Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. <i>Archives of Dermatological Research</i> , 2021 , 1	3.3	10	
36	Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study. <i>Dermatologic Therapy</i> , 2021 , e15214	2.2	9	
35	Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. <i>Journal of Dermatological Treatment</i> , 2020 , 1	2.8	8	
34	Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e680-e682	4.6	7	
33	Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study <i>Journal of Dermatological Treatment</i> , 2022 , 1-5	2.8	7	
32	New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding. <i>Dermatologic Therapy</i> , 2021 , 34, e14475	2.2	7	
31	Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. <i>Journal of Dermatological Treatment</i> ,1-8	2.8	7	
30	New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?. <i>Biomedicines</i> , 2021 , 9,	4.8	5	
29	Ocular Manifestations in Psoriasis Screening (OcMaPS) Questionnaire: A Useful Tool to Reveal Misdiagnosed Ocular Involvement in Psoriasis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5	
28	Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study <i>Dermatologic Therapy</i> , 2022 , e15524	2.2	5	
27	Psychological teleconsultations in patients suffering from chronic skin diseases during the COVID-19 era: a service to improve patientsSquality of life. <i>Journal of Dermatological Treatment</i> , 2020 , 1-2	2.8	4	
26	QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study. <i>International Journal of Dermatology</i> , 2021 , 60, 352-357	1.7	4	
25	MRI in Pregnancy and Precision Medicine: A Review from Literature <i>Journal of Personalized Medicine</i> , 2021 , 12,	3.6	4	
24	Secukinumab: a potential safe option in psoriasis patients affected by multiple sclerosis?. <i>International Journal of Dermatology</i> , 2020 , 59, e308-e309	1.7	3	
23	QuantiFERON-TB Gold conversion is not uncommon in patients with psoriasis undergoing anti-tumour necrosis factor-Itherapy. <i>British Journal of Dermatology</i> , 2020 , 183, 977-978	4	3	
22	Secukinumab during pregnancy: a case report and review of literature. <i>Journal of Dermatological Treatment</i> , 2020 , 1-2	2.8	3	
21	New-onset lichen planus arising after COVID-19 vaccination Dermatologic Therapy, 2022, e15374	2.2	3	
20	Eczematous drug eruption in psoriasis patients under anti-IL-17A: does IL-22 play a key role?. Clinical and Experimental Dermatology, 2021,	1.8	3	

19	Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, e211-e212	4.5	3
18	Low dose oral corticosteroids, microneedling, and topical 5-fluorouracil: A novel treatment for recalcitrant pediatric vitiligo. <i>Pediatric Dermatology</i> , 2021 , 38, 322-323	1.9	3
17	A case of generalized granuloma annulare successfully treated by hydroxychloroquine. <i>Dermatologic Therapy</i> , 2020 , 33, e13894	2.2	2
16	Chronic cutaneous ulcers management in dermatologic department during COVID-19 era. <i>International Wound Journal</i> , 2020 , 17, 1517-1518	2.6	2
15	A case of severe psoriasis in a 84-year-old women successfully treated with ixekizumab. <i>Dermatologic Therapy</i> , 2020 , 33, e13299	2.2	2
14	Impact of current antipsoriatic systemic treatments on male and female fertility: what endocrinologists need to know. <i>Minerva Endocrinology</i> , 2021 , 46, 350-362	2.5	2
13	A Case of Ofuji Disease Successfully Treated with the Combination of Low-Dose Indomethacin and Topical Tacrolimus. <i>Case Reports in Dermatology</i> , 2020 , 12, 155-158	1.1	2
12	The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 1135-1147	4.4	2
11	Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome. <i>International Wound Journal</i> , 2020 , 17, 1528-1531	2.6	1
10	A case of esophageal candidiasis in a psoriatic patient treated with ixekizumab: Should treatment be discontinued?. <i>Dermatologic Therapy</i> , 2022 , e15361	2.2	1
9	Skin Needling in Combination with Antimicrobial Peptides for the Treatment of Keloids: A Novel Perspective Proposal and Approach for Skin Scars. <i>Dermatology</i> , 2020 , 236, 601-602	4.4	1
8	Neoadjuvant use of methotrexate in eosinophilic angiocentric fibrosis of upper lip and hard palate: A case report. <i>Dermatologic Therapy</i> , 2021 , 34, e15094	2.2	1
7	Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-K\(\bar{B}\)ter-Hauser Syndrome: Insight into the Role of Hormones in HS. Skin Appendage Disorders, 2020 , 6, 366-369	1.4	O
6	Giant nodular melanoma of the nose in a 78-year-old female refusing complete excision. <i>Dermatologic Therapy</i> , 2020 , 33, e14056	2.2	O
5	Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and PatientsSAssessment <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2022 , 15, 661-673	2.9	O
4	A case of erythrodermic psoriasis successfully treated with apremilast. <i>Dermatologic Therapy</i> , 2021 , e1	5204	
3	Etanercept for pediatric acrodermatitis continua of Hallopeau: A case report and literature review. <i>Dermatologic Therapy</i> , 2020 , 33, e14046	2.2	
2	An atypical ear nodule. Indian Journal of Dermatology, Venereology and Leprology, 2021, 1-2	0.8	

SMS support group in the management of acne: A useful tool to increase adherence to treatment. Dermatologic Therapy, **2021**, 34, e14663

2.2